Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

The VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers.

Kurzrock R, Ball DW, Zahurak ML, Nelkin BD, Subbiah V, Ahmed S, O'Connor A, Karunsena E, Parkinson RM, Bishop JA, Ha Y, Sharma R, Gocke CD, Zinner R, Rudek MA, Sherman SI, Azad NS.

Clin Cancer Res. 2019 Jun 11. pii: clincanres.1881.2018. doi: 10.1158/1078-0432.CCR-18-1881. [Epub ahead of print]

PMID:
31186313
2.

The DNA Damaging Revolution: PARP Inhibitors and Beyond.

Yap TA, Plummer R, Azad NS, Helleday T.

Am Soc Clin Oncol Educ Book. 2019 Jan;39:185-195. doi: 10.1200/EDBK_238473. Epub 2019 May 17.

PMID:
31099635
3.

Programmed Cell Death Ligand-1 (PD-L1) and CD8 Expression Profiling Identify an Immunologic Subtype of Pancreatic Ductal Adenocarcinomas with Favorable Survival.

Danilova L, Ho WJ, Zhu Q, Vithayathil T, De Jesus-Acosta A, Azad NS, Laheru DA, Fertig EJ, Anders R, Jaffee EM, Yarchoan M.

Cancer Immunol Res. 2019 Jun;7(6):886-895. doi: 10.1158/2326-6066.CIR-18-0822. Epub 2019 May 1.

PMID:
31043417
4.

PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers.

Yarchoan M, Albacker LA, Hopkins AC, Montesion M, Murugesan K, Vithayathil TT, Zaidi N, Azad NS, Laheru DA, Frampton GM, Jaffee EM.

JCI Insight. 2019 Mar 21;4(6). pii: 126908. doi: 10.1172/jci.insight.126908. eCollection 2019 Mar 21.

5.

Correction to: Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer.

Goff LW, Azad NS, Stein S, Whisenant JG, Koyama T, Vaishampayan U, Hochster H, Connolly R, Weise A, LoRusso PM, Salaria SN, El-Rifai W, Berlin JD.

Invest New Drugs. 2018 Dec;36(6):1158. doi: 10.1007/s10637-018-0679-5.

PMID:
30334109
6.

Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer.

Goff LW, Azad NS, Stein S, Whisenant JG, Koyama T, Vaishampayan U, Hochster H, Connolly R, Weise A, LoRusso PM, Salaria SN, El-Rifai W, Berlin JD.

Invest New Drugs. 2019 Apr;37(2):315-322. doi: 10.1007/s10637-018-0663-0. Epub 2018 Sep 6. Erratum in: Invest New Drugs. 2018 Oct 18;:.

PMID:
30191522
7.

Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease.

Boyiadzis MM, Kirkwood JM, Marshall JL, Pritchard CC, Azad NS, Gulley JL.

J Immunother Cancer. 2018 May 14;6(1):35. doi: 10.1186/s40425-018-0342-x.

8.

The role of epigenetic therapies in colorectal cancer.

Baretti M, Azad NS.

Curr Probl Cancer. 2018 Nov;42(6):530-547. doi: 10.1016/j.currproblcancer.2018.03.001. Epub 2018 Mar 12. Review.

PMID:
29625794
9.

The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma.

Shroff RT, Yarchoan M, O'Connor A, Gallagher D, Zahurak ML, Rosner G, Ohaji C, Sartorius-Mergenthaler S, Parkinson R, Subbiah V, Zinner R, Azad NS.

Br J Cancer. 2018 Jan;118(2):e2. doi: 10.1038/bjc.2017.418. Epub 2018 Jan 9. No abstract available.

10.

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.

Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, Wong F, Azad NS, Rucki AA, Laheru D, Donehower R, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Greten TF, Duffy AG, Ciombor KK, Eyring AD, Lam BH, Joe A, Kang SP, Holdhoff M, Danilova L, Cope L, Meyer C, Zhou S, Goldberg RM, Armstrong DK, Bever KM, Fader AN, Taube J, Housseau F, Spetzler D, Xiao N, Pardoll DM, Papadopoulos N, Kinzler KW, Eshleman JR, Vogelstein B, Anders RA, Diaz LA Jr.

Science. 2017 Jul 28;357(6349):409-413. doi: 10.1126/science.aan6733. Epub 2017 Jun 8.

11.

Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer.

Yarchoan M, Myzak MC, Johnson BA 3rd, De Jesus-Acosta A, Le DT, Jaffee EM, Azad NS, Donehower RC, Zheng L, Oberstein PE, Fine RL, Laheru DA, Goggins M.

Oncotarget. 2017 Jul 4;8(27):44073-44081. doi: 10.18632/oncotarget.17237.

12.

The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma.

Shroff RT, Yarchoan M, O'Connor A, Gallagher D, Zahurak ML, Rosner G, Ohaji C, Sartorius-Mergenthaler S, Parkinson R, Subbiah V, Zinner R, Azad NS.

Br J Cancer. 2017 May 23;116(11):1402-1407. doi: 10.1038/bjc.2017.119. Epub 2017 Apr 25. Erratum in: Br J Cancer. 2018 Jan 09;:.

13.

Correction: A new immunohistochemistry prognostic score (IPS) for recurrence and survival in resected pancreatic neuroendocrine tumors (PanNET).

Viúdez A, Carvalho FL, Maleki Z, Zahurak M, Laheru D, Stark A, Azad NS, Wolfgang CL, Baylin S, Herman JG, De Jesus-Acosta A.

Oncotarget. 2017 Mar 14;8(11):18617. doi: 10.18632/oncotarget.16155. No abstract available.

14.

Academic Cancer Center Phase I Program Development.

Frankel AE, Flaherty KT, Weiner GJ, Chen R, Azad NS, Pishvaian MJ, Thompson JA, Taylor MH, Mahadevan D, Lockhart AC, Vaishampayan UN, Berlin JD, Smith DC, Sarantopoulos J, Riese M, Saleh MN, Ahn C, Frenkel EP.

Oncologist. 2017 Apr;22(4):369-374. doi: 10.1634/theoncologist.2016-0409. Epub 2017 Mar 17.

15.

Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand up 2 cancer study.

Azad NS, El-Khoueiry A, Yin J, Oberg AL, Flynn P, Adkins D, Sharma A, Weisenberger DJ, Brown T, Medvari P, Jones PA, Easwaran H, Kamel I, Bahary N, Kim G, Picus J, Pitot HC, Erlichman C, Donehower R, Shen H, Laird PW, Piekarz R, Baylin S, Ahuja N.

Oncotarget. 2017 May 23;8(21):35326-35338. doi: 10.18632/oncotarget.15108.

16.

A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers.

Reiss KA, Herman JM, Armstrong D, Zahurak M, Fyles A, Brade A, Milosevic M, Dawson LA, Scardina A, Fischer P, Hacker-Prietz A, Kinders RJ, Wang L, Chen A, Temkin S, Horiba N, Stayner LA, Siu LL, Azad NS.

Gynecol Oncol. 2017 Mar;144(3):486-490. doi: 10.1016/j.ygyno.2017.01.016. Epub 2017 Jan 18.

17.

A phase 1 dose-escalation study of NEO-102 in patients with refractory colon and pancreatic cancer.

Beg MS, Azad NS, Patel SP, Torrealba J, Mavroukakis S, Beatson MA, Wang XP, Arlen PM, Morse MA.

Cancer Chemother Pharmacol. 2016 Sep;78(3):577-84. doi: 10.1007/s00280-016-3108-5. Epub 2016 Jul 23.

18.

A new immunohistochemistry prognostic score (IPS) for recurrence and survival in resected pancreatic neuroendocrine tumors (PanNET).

Viúdez A, Carvalho FL, Maleki Z, Zahurak M, Laheru D, Stark A, Azad NS, Wolfgang CL, Baylin S, Herman JG, De Jesus-Acosta A.

Oncotarget. 2016 May 3;7(18):24950-61. doi: 10.18632/oncotarget.7436. Erratum in: Oncotarget. 2017 Mar 14;8(11):18617.

19.

Mutational profiling of colorectal cancers with microsatellite instability.

Lin EI, Tseng LH, Gocke CD, Reil S, Le DT, Azad NS, Eshleman JR.

Oncotarget. 2015 Dec 8;6(39):42334-44. doi: 10.18632/oncotarget.5997.

20.

Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers.

Haley L, Tseng LH, Zheng G, Dudley J, Anderson DA, Azad NS, Gocke CD, Eshleman JR, Lin MT.

Mod Pathol. 2015 Oct;28(10):1390-9. doi: 10.1038/modpathol.2015.86. Epub 2015 Jul 31.

21.

A robust and rapid liquid chromatography tandem mass spectrometric method for the quantitative analysis of 5-azacytidine.

Anders NM, Wanjiku TM, He P, Azad NS, Rudek MA.

Biomed Chromatogr. 2016 Mar;30(3):494-6. doi: 10.1002/bmc.3562. Epub 2015 Aug 17.

22.

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA Jr.

N Engl J Med. 2015 Jun 25;372(26):2509-20. doi: 10.1056/NEJMoa1500596. Epub 2015 May 30.

23.

Epigenetic therapy for solid tumors: from bench science to clinical trials.

Juo YY, Gong XJ, Mishra A, Cui X, Baylin SB, Azad NS, Ahuja N.

Epigenomics. 2015;7(2):215-35. doi: 10.2217/epi.14.73. Review.

PMID:
25942532
24.

Analysis of fiducials implanted during EUS for patients with localized rectal cancer receiving high-dose rate endorectal brachytherapy.

Moningi S, Walker AJ, Malayeri AA, Rosati LM, Gearhart SL, Efron JE, Wick EC, Azad NS, Armour EP, Le Y, Herman JM, Shin EJ.

Gastrointest Endosc. 2015 Mar;81(3):765-769.e1. doi: 10.1016/j.gie.2014.11.004. No abstract available.

25.

A Phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy in patients with advanced solid malignancies and peritoneal carcinomatosis.

Reiss KA, Herman JM, Zahurak M, Brade A, Dawson LA, Scardina A, Joffe C, Petito E, Hacker-Prietz A, Kinders RJ, Wang L, Chen A, Temkin S, Horiba N, Siu LL, Azad NS.

Clin Cancer Res. 2015 Jan 1;21(1):68-76. doi: 10.1158/1078-0432.CCR-14-1552. Epub 2014 Oct 29.

26.

A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours.

Wilky BA, Rudek MA, Ahmed S, Laheru DA, Cosgrove D, Donehower RC, Nelkin B, Ball D, Doyle LA, Chen H, Ye X, Bigley G, Womack C, Azad NS.

Br J Cancer. 2015 Jan 6;112(1):24-31. doi: 10.1038/bjc.2014.515. Epub 2014 Sep 30.

27.

Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab.

Tabernero J, Chawla SP, Kindler H, Reckamp K, Chiorean EG, Azad NS, Lockhart AC, Hsu CP, Baker NF, Galimi F, Beltran P, Baselga J.

Target Oncol. 2015 Mar;10(1):65-76. doi: 10.1007/s11523-014-0315-z. Epub 2014 May 11.

28.

The utility of molecular testing in colorectal cancer: the promise needs progress.

Azad NS, Diaz LA Jr.

Oncology (Williston Park). 2014 Feb;28(2):118-9, 125. No abstract available.

29.

A randomized pilot trial of a telephone-based couples intervention for physical intimacy and sexual concerns in colorectal cancer.

Barsky Reese J, Porter LS, Regan KR, Keefe FJ, Azad NS, Diaz LA Jr, Herman JM, Haythornthwaite JA.

Psychooncology. 2014 Sep;23(9):1005-13. doi: 10.1002/pon.3508. Epub 2014 Feb 26.

30.

Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers.

Li H, Chiappinelli KB, Guzzetta AA, Easwaran H, Yen RW, Vatapalli R, Topper MJ, Luo J, Connolly RM, Azad NS, Stearns V, Pardoll DM, Davidson N, Jones PA, Slamon DJ, Baylin SB, Zahnow CA, Ahuja N.

Oncotarget. 2014 Feb 15;5(3):587-98.

31.

Detection of circulating tumor DNA in early- and late-stage human malignancies.

Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, Antonarakis ES, Azad NS, Bardelli A, Brem H, Cameron JL, Lee CC, Fecher LA, Gallia GL, Gibbs P, Le D, Giuntoli RL, Goggins M, Hogarty MD, Holdhoff M, Hong SM, Jiao Y, Juhl HH, Kim JJ, Siravegna G, Laheru DA, Lauricella C, Lim M, Lipson EJ, Marie SK, Netto GJ, Oliner KS, Olivi A, Olsson L, Riggins GJ, Sartore-Bianchi A, Schmidt K, Shih lM, Oba-Shinjo SM, Siena S, Theodorescu D, Tie J, Harkins TT, Veronese S, Wang TL, Weingart JD, Wolfgang CL, Wood LD, Xing D, Hruban RH, Wu J, Allen PJ, Schmidt CM, Choti MA, Velculescu VE, Kinzler KW, Vogelstein B, Papadopoulos N, Diaz LA Jr.

Sci Transl Med. 2014 Feb 19;6(224):224ra24. doi: 10.1126/scitranslmed.3007094.

32.

Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases.

Karagkounis G, Torbenson MS, Daniel HD, Azad NS, Diaz LA Jr, Donehower RC, Hirose K, Ahuja N, Pawlik TM, Choti MA.

Cancer. 2013 Dec 1;119(23):4137-44. doi: 10.1002/cncr.28347. Epub 2013 Sep 19.

33.

Gastrointestinal ostomies and sexual outcomes: a comparison of colorectal cancer patients by ostomy status.

Reese JB, Finan PH, Haythornthwaite JA, Kadan M, Regan KR, Herman JM, Efron J, Diaz LA Jr, Azad NS.

Support Care Cancer. 2014 Feb;22(2):461-8. doi: 10.1007/s00520-013-1998-x. Epub 2013 Oct 5.

34.

CHFR silencing or microsatellite instability is associated with increased antitumor activity of docetaxel or gemcitabine in colorectal cancer.

Pelosof L, Yerram SR, Ahuja N, Delmas A, Danilova L, Herman JG, Azad NS.

Int J Cancer. 2014 Feb 1;134(3):596-605. doi: 10.1002/ijc.28390. Epub 2013 Aug 24.

35.

DNA-intercalators causing rapid re-expression of methylated and silenced genes in cancer cells.

Hossain MZ, Healey MA, Lee C, Poh W, Yerram SR, Patel K, Azad NS, Herman JG, Kern SE.

Oncotarget. 2013 Feb;4(2):298-309.

36.

The quality-of-life effects of neoadjuvant chemoradiation in locally advanced rectal cancer.

Herman JM, Narang AK, Griffith KA, Zalupski MM, Reese JB, Gearhart SL, Azad NS, Chan J, Olsen L, Efron JE, Lawrence TS, Ben-Josef E.

Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):e15-9. doi: 10.1016/j.ijrobp.2012.09.006. Epub 2012 Oct 9.

37.

Clinicopathologic Comparison of High-Dose-Rate Endorectal Brachytherapy versus Conventional Chemoradiotherapy in the Neoadjuvant Setting for Resectable Stages II and III Low Rectal Cancer.

Smith JA, Wild AT, Singhi A, Raman SP, Qiu H, Kumar R, Hacker-Prietz A, Hruban RH, Kamel IR, Efron J, Wick EC, Azad NS, Diaz LA Jr, Le Y, Armour EP, Gearhart SL, Herman JM.

Int J Surg Oncol. 2012;2012:406568. doi: 10.1155/2012/406568. Epub 2012 Jul 8.

38.

Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the United States.

Reyes DK, Vossen JA, Kamel IR, Azad NS, Wahlin TA, Torbenson MS, Choti MA, Geschwind JF.

Cancer J. 2009 Nov-Dec;15(6):526-32. doi: 10.1097/PPO.0b013e3181c5214b.

39.

[No title available]

Azad NS, Aragon-Ching JB, Kong HH.

Clin Cancer Res. 2009 Dec 15;15(24):7749. No abstract available.

PMID:
20008856
Free Article
40.

Esophageal polypoidal mass: presentation of an uncommon pleomorphic carcinoma.

Yakoob J, Abbas Z, Jafri W, Azad NS.

J Pak Med Assoc. 2009 Sep;59(9):639-41.

41.

Will histopathology survive in Pakistan?

Ahmad Z, Qureshi A, Azad NS, Khurshid A.

J Clin Pathol. 2009 Jun;62(6):575. doi: 10.1136/jcp.2009.065193. No abstract available.

PMID:
19474365
42.

Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy.

Azad NS, Aragon-Ching JB, Dahut WL, Gutierrez M, Figg WD, Jain L, Steinberg SM, Turner ML, Kohn EC, Kong HH.

Clin Cancer Res. 2009 Feb 15;15(4):1411-6. doi: 10.1158/1078-0432.CCR-08-1141.

43.

Granulomatous gastritis: a diagnostic dilemma?

Kamani L, Mumtaz K, Azad NS, Jafri W.

Singapore Med J. 2008 Sep;49(9):e222-4.

44.

Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.

Azad NS, Posadas EM, Kwitkowski VE, Steinberg SM, Jain L, Annunziata CM, Minasian L, Sarosy G, Kotz HL, Premkumar A, Cao L, McNally D, Chow C, Chen HX, Wright JJ, Figg WD, Kohn EC.

J Clin Oncol. 2008 Aug 1;26(22):3709-14. doi: 10.1200/JCO.2007.10.8332. Erratum in: J Clin Oncol. 2008 Sep 10;26(26):4363. Figg, William D [added].

PMID:
18669456
45.

Rhinosporidiosis presenting as an urethral polyp.

Azad NS, Ahmad Z, Kayani N.

J Coll Physicians Surg Pak. 2008 May;18(5):314-5. doi: 05.2008/JCPSP.314315.

PMID:
18541092
46.

Frequency of primary solid malignant neoplasms in different age groups as seen in our practice.

Ahmed Z, Azad NS, Rauf F, Yaqoob N, Husain A, Ahsan A, Ahmed R, Kayani N, Pervez S, Hassan SH.

J Ayub Med Coll Abbottabad. 2007 Jul-Sep;19(3):56-63.

PMID:
18444593
47.

Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy.

Azad NS, Annunziata CM, Steinberg SM, Minasian L, Premkumar A, Chow C, Kotz HL, Kohn EC.

Cancer. 2008 Apr 15;112(8):1726-32. doi: 10.1002/cncr.23374.

48.

Thymoma : a clinicopathologic association of world health organization histologic subtype and invasive behaviour.

Azad NS, Ahmad Z, Ahsan A, Fatimi S, Ahmed R, Kayani N, Pervez S, Hasan SH.

J Coll Physicians Surg Pak. 2007 Nov;17(11):658-61.

PMID:
18070571
49.

Gastric carcinoma: typing, staging, lymph node and resection margin status on gastrectomy specimens.

Ahmad Z, Idrees R, Azad NS, Ahmed R, Ahsan A, Asghar N.

J Coll Physicians Surg Pak. 2007 Sep;17(9):539-42.

PMID:
17903401
50.

Frequency of primary solid malignant neoplasms in both sexes, as seen in our practice.

Ahmad Z, Azad NS, Yaqoob N, Husain A, Ahsan A, Khan AN, Ahmed R, Kayani N, Pervez S, Hassan SH.

J Ayub Med Coll Abbottabad. 2007 Jan-Mar;19(1):53-5.

PMID:
17867482

Supplemental Content

Support Center